Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 3Active not recruiting 3Completed 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Liver Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Solid Malignancies 1Seminoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Non Small Cell Lung Cancer NSCLC 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Metastatic Malignant Female Reproductive System Neoplasm 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Immunotherapy 1Hydronephrosis 1

Interventions

durvalumab 7Bevacizumab 6tremelimumab 3Nivolumab 3lenvatinib 2fludarabine 2Cyclophosphamide 2zimberelimab 1toripalimab 1ropidoxuridine 1relatlimab 1pembrolizumab 1fludarabine phosphate 1atezolizumab 1X-Rays 1Technetium Tc 99m Aggregated Albumin 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radionuclide Imaging 1Platinum 1Photons 1Paclitaxel 1Observation 1Long-Term Potentiation 1Lidocaine 1Immunotherapy 1Immunoglobulin G 1IMC-001 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Liver Neoplasms × tremelimumab × Clear all
NCT03937830 2026-06-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05883644 2026-04-30

SIERRA

AstraZeneca

Phase 3 Active not recruiting
111 enrolled
Gastrointestinal

Liver Neoplasms

NCT05301842 2026-04-07

EMERALD-3

AstraZeneca

Phase 3 Active not recruiting
760 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡